ResearchMetabolism
Retatrutide: what the phase 2 and phase 3 trials have shown so far, and what is still missing
Retatrutide, a once-weekly drug acting on three hormone receptors, now has published phase 3 trials in obesity and type 2 diabetes. Here is how much weight participants lost, in whom, with which side effects, and what the trials have not yet measured.
8 min read